Calendario›REGN›REGN7041 · TITAN

REGN7041 · TITAN

A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

Ensayo de REGENERON PHARMACEUTICALS, INC. en Active Noninfectious Uveitis Affecting the Posterior Segment (del registro, en inglés).

Fase

Fase 1/2

Estado

Interrumpido

Participantes

1

previstos

Centros

5

Fin del objetivo primario

jul 2026

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en dic 2025.

Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Unfavorable benefit-risk assessment».

Qué mide

Occurrence of Treatment-Emergent Adverse Events (TEAEs) (Through Week 24) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an experimental drug called REGN7041 (also referred to as "study drug"). The study is focused on patients who have active inflammation inside of the eye without any signs of infection. The aim of the study is to see how safe and tolerable the study drug is. This is the first time the study drug is being tested in humans. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood and the fluid in the eye at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07218770), actualizada en ago 2026.